Skip to main content

Actinic Keratosis (AK)

4
Pipeline Programs
4
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
1
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Leo Pharma
Leo PharmaDenmark - Ballerup
2 programs
2
Ingenol Mebutate Gel, 0.015%Phase 41 trial
Ingenol Mebutate Gel, 0.015%Phase 41 trial
Active Trials
NCT02406014Completed502Est. Jun 2016
NCT01926496Completed485Est. Jul 2019
Dr. Reddy's Laboratories
1 program
1
Low dose DFD07 once dailyPhase 2/31 trial
Active Trials
NCT03116698Completed240Est. Jul 2018
Biocorp
BiocorpFrance - Issoire
1 program
1
HW211026Phase 12 trials
Active Trials
NCT07513454Not Yet Recruiting80Est. Dec 2027
NCT07318675Recruiting40Est. Mar 2026
Rubedo Life Sciences
Rubedo Life SciencesCA - Sunnyvale
1 program
RLS-1496 1.0% creamPHASE_1_21 trial
Active Trials
NCT07340697Recruiting24Est. May 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Leo PharmaIngenol Mebutate Gel, 0.015%
Leo PharmaIngenol Mebutate Gel, 0.015%
Dr. Reddy's LaboratoriesLow dose DFD07 once daily
BiocorpHW211026
Rubedo Life SciencesRLS-1496 1.0% cream
BiocorpHW211026

Clinical Trials (6)

Total enrollment: 1,371 patients across 6 trials

NCT02406014Leo PharmaIngenol Mebutate Gel, 0.015%

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Start: Apr 2015Est. completion: Jun 2016502 patients
Phase 4Completed
NCT01926496Leo PharmaIngenol Mebutate Gel, 0.015%

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

Start: Sep 2013Est. completion: Jul 2019485 patients
Phase 4Completed
NCT03116698Dr. Reddy's LaboratoriesLow dose DFD07 once daily

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

Start: Feb 2017Est. completion: Jul 2018240 patients
Phase 2/3Completed

A Phase 2 Study of HW211026 in Participants With Actinic Keratosis

Start: May 2026Est. completion: Dec 202780 patients
Phase 2Not Yet Recruiting

Evaluate RLS-1496 Topical Cream for Actinic Keratosis

Start: Jan 2026Est. completion: May 202624 patients
Phase 1/2Recruiting

A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.

Start: Dec 2025Est. completion: Mar 202640 patients
Phase 1Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 1,371 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.